F8 and hemophilia A: A recent study demonstrated an ex vivo gene therapy approach in which human hepatocytes were genetically modified to express coagulation factor VIII (FVIII) and subsequently transplanted into immunocompromised hemophilia A (HA) mice, resulting in therapeutic benefits and offering a potential treatment strategy for HA [24].